{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:02:48Z","timestamp":1794960168945,"version":"4.9.1"},"reference-count":272,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82270646"],"award-info":[{"award-number":["82270646"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03832-x","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T10:04:09Z","timestamp":1766570649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Emerging nanomedicine for liver diseases treatment"],"prefix":"10.1186","volume":"23","author":[{"given":"Yawen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxue","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haozhen","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"issue":"8015","key":"3832_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41586-024-07465-2","volume":"630","author":"C Gribben","year":"2024","unstructured":"Gribben C, Galanakis V, Calderwood A, et al. Acquisition of epithelial plasticity in human chronic liver disease. Nature. 2024;630(8015):166\u201373.","journal-title":"Nature"},{"issue":"1","key":"3832_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/HEP.0000000000000479","volume":"81","author":"H Gilgenkrantz","year":"2025","unstructured":"Gilgenkrantz H, Paradis V, Lotersztajn S. Cell metabolism-based therapy for liver fibrosis, repair, and hepatocellular carcinoma. Hepatology. 2025;81(1):269\u201387.","journal-title":"Hepatology"},{"issue":"10","key":"3832_CR3","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41575-023-00832-w","volume":"20","author":"S Sharma","year":"2023","unstructured":"Sharma S, Le Guillou D, Chen JY. Cellular stress in the pathogenesis of nonalcoholic steatohepatitis and liver fibrosis. Nat Rev Gastroenterol Hepatol. 2023;20(10):662\u201378.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"3832_CR4","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jhep.2021.11.009","volume":"76","author":"E Scorletti","year":"2022","unstructured":"Scorletti E, Carr RM. A new perspective on NAFLD: focusing on lipid droplets. J Hepatol. 2022;76(4):934\u201345.","journal-title":"J Hepatol"},{"issue":"33","key":"3832_CR5","doi-asserted-by":"publisher","first-page":"e2301352","DOI":"10.1002\/adma.202301352","volume":"35","author":"C Huang","year":"2023","unstructured":"Huang C, Xie T, Liu Y, et al. A sodium Alginate-Based multifunctional nanoplatform for synergistic Chemo-Immunotherapy of hepatocellular carcinoma. Adv Mater. 2023;35(33):e2301352.","journal-title":"Adv Mater"},{"key":"3832_CR6","doi-asserted-by":"publisher","unstructured":"Pallares RM, Consolino L, Wang A et al. Targeting metastasis with nanomedicine. Nat Reviews Bioeng. 2025;17. https:\/\/doi.org\/10.1038\/s44222-025-00358-7.","DOI":"10.1038\/s44222-025-00358-7"},{"issue":"1","key":"3832_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02072-z","volume":"10","author":"C Gan","year":"2025","unstructured":"Gan C, Yuan Y, Shen H, et al. Liver diseases: epidemiology, causes, trends and predictions. Signal Transduct Target Ther. 2025;10(1):33.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"3832_CR8","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/s41591-023-02265-z","volume":"29","author":"P Gin\u00e8s","year":"2023","unstructured":"Gin\u00e8s P, Thiele M, Graupera I, et al. Screening for fibrosis to diagnose liver diseases early: the LIVERSCREEN project. Nat Med. 2023;29(4):774\u20135.","journal-title":"Nat Med"},{"issue":"32","key":"3832_CR9","doi-asserted-by":"publisher","first-page":"20861","DOI":"10.1021\/acsnano.4c02380","volume":"18","author":"J Liu","year":"2024","unstructured":"Liu J, Liu J, Mu W, et al. Delivery strategy to enhance the therapeutic efficacy of liver fibrosis via nanoparticle drug delivery systems. ACS Nano. 2024;18(32):20861\u201385.","journal-title":"ACS Nano"},{"issue":"3","key":"3832_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41565-024-01833-9","volume":"20","author":"M O\u2019Brien Laramy","year":"2025","unstructured":"O\u2019Brien Laramy M, Foley DA, Pak RH, et al. Chemistry, manufacturing and controls strategies for using novel excipients in lipid nanoparticles. Nat Nanotechnol. 2025;20(3):331\u201344.","journal-title":"Nat Nanotechnol"},{"key":"3832_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114965","volume":"199","author":"S Zeng","year":"2023","unstructured":"Zeng S, Chen Y, Zhou F, et al. Recent advances and prospects for lipid-based nanoparticles as drug carriers in the treatment of human retinal diseases. Adv Drug Deliv Rev. 2023;199:114965.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"3832_CR12","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1016\/j.apsb.2023.05.018","volume":"13","author":"Q Liu","year":"2023","unstructured":"Liu Q, Zou J, Chen Z, He W, Wu W. Current research trends of nanomedicines. Acta Pharm Sin B. 2023;13(11):4391\u2013416.","journal-title":"Acta Pharm Sin B"},{"issue":"20","key":"3832_CR13","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1039\/D3TB02766J","volume":"12","author":"R Chu","year":"2024","unstructured":"Chu R, Wang Y, Kong J, Pan T, Yang Y, He J. Lipid nanoparticles as the drug carrier for targeted therapy of hepatic disorders. J Mater Chem B. 2024;12(20):4759\u201384.","journal-title":"J Mater Chem B"},{"key":"3832_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","volume":"121","author":"T Higashi","year":"2017","unstructured":"Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 2017;121:27\u201342.","journal-title":"Adv Drug Deliv Rev"},{"key":"3832_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123510","volume":"324","author":"H Zhang","year":"2026","unstructured":"Zhang H, Xing J, Sun M, et al. Engineered exosomes for targeted MicroRNA delivery to reverse liver fibrosis. Biomaterials. 2026;324:123510.","journal-title":"Biomaterials"},{"key":"3832_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101938","volume":"33","author":"H Ding","year":"2025","unstructured":"Ding H, Liu Y, Xia T, et al. Biomimetic membrane-coated nanoparticles for targeted synergistic therapy of homocysteine-induced atherosclerosis: dual modulation of cholesterol efflux and reactive oxygen species scavenging. Mater Today Bio. 2025;33:101938.","journal-title":"Mater Today Bio"},{"issue":"3","key":"3832_CR17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jhep.2021.04.055","volume":"75","author":"HJ Cordell","year":"2021","unstructured":"Cordell HJ, Fryett JJ, Ueno K, et al. An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs. J Hepatol. 2021;75(3):572\u201381.","journal-title":"J Hepatol"},{"key":"3832_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2022.957572","volume":"10","author":"F Hejabi","year":"2022","unstructured":"Hejabi F, Abbaszadeh MS, Taji S, O\u2019Neill A, Farjadian F, Doroudian M. Nanocarriers: A novel strategy for the delivery of CRISPR\/Cas systems. Front Chem. 2022;10:957572.","journal-title":"Front Chem"},{"issue":"1","key":"3832_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3748\/wjg.v22.i1.8","volume":"22","author":"MS Kim","year":"2016","unstructured":"Kim MS, Ong M, Qu X. Optimal management for alcoholic liver disease: conventional medications, natural therapy or combination? World J Gastroenterol. 2016;22(1):8\u201323.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"3832_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102343","volume":"48","author":"X Meng","year":"2024","unstructured":"Meng X, Wang L, Du YC, Cheng D, Zeng T. PPAR\u03b2\/\u03b4 as a promising molecular drug target for liver diseases: a focused review. Clin Res Hepatol Gastroenterol. 2024;48(6):102343.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"3832_CR21","first-page":"1","volume":"45","author":"J Zhao","year":"2025","unstructured":"Zhao J, Zhi Y, Ren H, Wang J, Zhao Y. Emerging biotechnologies for engineering liver organoids. Bioact Mater. 2025;45:1\u201318.","journal-title":"Bioact Mater"},{"issue":"30","key":"3832_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202403516","volume":"11","author":"H Liu","year":"2024","unstructured":"Liu H, Yin G, Kohlhepp MS, et al. Dissecting acute drug-induced hepatotoxicity and therapeutic responses of steatotic liver disease using primary mouse liver and blood cells in a liver-on-a-chip model. Adv Sci. 2024;11(30):e2403516.","journal-title":"Adv Sci"},{"key":"3832_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106786","volume":"192","author":"YY Qiu","year":"2023","unstructured":"Qiu YY, Zhang J, Zeng FY, Zhu YZ. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Pharmacol Res. 2023;192:106786.","journal-title":"Pharmacol Res"},{"issue":"2","key":"3832_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/1061186X.2020.1812614","volume":"29","author":"M Ghaferi","year":"2021","unstructured":"Ghaferi M, Koohi Moftakhari Esfahani M, Raza A, Al Harthi S, Ebrahimi Shahmabadi H, Alavi SE. Mesoporous silica nanoparticles: synthesis methods and their therapeutic use-recent advances. J Drug Target. 2021;29(2):131\u201354.","journal-title":"J Drug Target"},{"key":"3832_CR25","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.2147\/DDDT.S207277","volume":"13","author":"DY Zhang","year":"2019","unstructured":"Zhang DY, Zhu L, Liu HN, et al. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease. Drug Des Devel Ther. 2019;13:2249\u201370.","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"3832_CR26","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1016\/j.apsb.2020.09.004","volume":"10","author":"G Ji","year":"2020","unstructured":"Ji G, Ma L, Yao H, et al. Precise delivery of obeticholic acid via nanoapproach for triggering natural killer T cell-mediated liver cancer immunotherapy. Acta Pharm Sin B. 2020;10(11):2171\u201382.","journal-title":"Acta Pharm Sin B"},{"issue":"17","key":"3832_CR27","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.3390\/nu15173733","volume":"15","author":"S Vogli","year":"2023","unstructured":"Vogli S, Naska A, Marinos G, Kasdagli MI, Orfanos P. The effect of vitamin E supplementation on serum aminotransferases in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. Nutrients. 2023;15(17):3733. https:\/\/doi.org\/10.3390\/nu15173733.","journal-title":"Nutrients"},{"issue":"9","key":"3832_CR28","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1039\/D1BM00119A","volume":"9","author":"RR Zheng","year":"2021","unstructured":"Zheng RR, Zhao LP, Liu LS, et al. Self-delivery nanomedicine to overcome drug resistance for synergistic chemotherapy. Biomater Sci. 2021;9(9):3445\u201352.","journal-title":"Biomater Sci"},{"issue":"1","key":"3832_CR29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/gutjnl-2016-312431","volume":"66","author":"Y Rotman","year":"2017","unstructured":"Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66(1):180\u201390.","journal-title":"Gut"},{"issue":"10","key":"3832_CR30","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/gels8100658","volume":"8","author":"P Dehghani","year":"2022","unstructured":"Dehghani P, Akbari A, Saadatkish M, Varshosaz J, Kouhi M, Bodaghi M. Acceleration of wound healing in rats by modified lignocellulose based sponge containing Pentoxifylline loaded Lecithin\/Chitosan nanoparticles. Gels. 2022;8(10):658. https:\/\/doi.org\/10.3390\/gels8100658.","journal-title":"Gels"},{"issue":"1","key":"3832_CR31","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cmet.2018.08.020","volume":"29","author":"JSV Lally","year":"2019","unstructured":"Lally JSV, Ghoshal S, DePeralta DK, et al. Inhibition of Acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma. Cell Metab. 2019;29(1):174\u2013e1825.","journal-title":"Cell Metab"},{"key":"3832_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123599","volume":"325","author":"L Zhu","year":"2026","unstructured":"Zhu L, Zu M, Wu F, et al. Cancer-associated fibroblasts regulating nanomedicine to overcome Sorafenib resistance in hepatocellular carcinoma with portal vein tumor thrombus. Biomaterials. 2026;325:123599.","journal-title":"Biomaterials"},{"issue":"6","key":"3832_CR33","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","volume":"21","author":"MS Lee","year":"2020","unstructured":"Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808\u201320.","journal-title":"Lancet Oncol"},{"issue":"7","key":"3832_CR34","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1007\/s13346-024-01734-3","volume":"15","author":"C Pangua","year":"2025","unstructured":"Pangua C, Espuelas S, Sim\u00f3n JA, et al. Enhancing bevacizumab efficacy in a colorectal tumor mice model using dextran-coated albumin nanoparticles. Drug Deliv Transl Res. 2025;15(7):2354\u201371.","journal-title":"Drug Deliv Transl Res"},{"issue":"6","key":"3832_CR35","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.jhep.2023.08.017","volume":"79","author":"W Limousin","year":"2023","unstructured":"Limousin W, Laurent-Puig P, Ziol M, et al. Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab\/bevacizumab. J Hepatol. 2023;79(6):1450\u20138.","journal-title":"J Hepatol"},{"issue":"12","key":"3832_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12122051","volume":"12","author":"M Morais","year":"2023","unstructured":"Morais M, Machado V, Figueiredo P, et al. Silver nanoparticles (AgNPs) as enhancers of everolimus and radiotherapy sensitivity on clear cell renal cell carcinoma. Antioxidants. 2023;12(12):2051.","journal-title":"Antioxidants"},{"key":"3832_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106783","volume":"198","author":"F Yu","year":"2024","unstructured":"Yu F, Liu Z, Feng J, et al. Hyaluronic acid modified extracellular vesicles targeting hepatic stellate cells to attenuate hepatic fibrosis. Eur J Pharm Sci. 2024;198:106783.","journal-title":"Eur J Pharm Sci"},{"key":"3832_CR38","doi-asserted-by":"crossref","unstructured":"Zhou RO, Zhang NY. Application of Pirfenidone-loaded fluorescence nanoparticles to inhibit hepatocellular carcinoma by modulating oxidative stress. J Fluoresc. 2025.","DOI":"10.1007\/s10895-025-04444-2"},{"issue":"3","key":"3832_CR39","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1096\/fj.201801344RR","volume":"33","author":"DG Song","year":"2019","unstructured":"Song DG, Kim D, Jung JW, et al. Glutamyl-prolyl-tRNA synthetase induces fibrotic extracellular matrix via both transcriptional and translational mechanisms. FASEB J. 2019;33(3):4341\u201354.","journal-title":"FASEB J"},{"key":"3832_CR40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.freeradbiomed.2022.05.017","volume":"187","author":"H Panda","year":"2022","unstructured":"Panda H, Suzuki M, Naito M, et al. Halofuginone micelle nanoparticles eradicate Nrf2-activated lung adenocarcinoma without systemic toxicity. Free Radic Biol Med. 2022;187:92\u2013104.","journal-title":"Free Radic Biol Med"},{"issue":"5","key":"3832_CR41","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","volume":"158","author":"N Chalasani","year":"2020","unstructured":"Chalasani N, Abdelmalek MF, Garcia-Tsao G, et al. Effects of Belapectin, an inhibitor of Galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology. 2020;158(5):1334\u2013e13455.","journal-title":"Gastroenterology"},{"key":"3832_CR42","doi-asserted-by":"crossref","unstructured":"Biswas S, Medina H SH, Barchi JJ Jr. Synthesis and cell-selective antitumor properties of amino acid conjugated tumor-associated carbohydrate antigen-coated gold nanoparticles. Carbohydr Res. 2015;405:93\u2013101.","DOI":"10.1016\/j.carres.2014.11.002"},{"issue":"7","key":"3832_CR43","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","volume":"158","author":"RF Schwabe","year":"2020","unstructured":"Schwabe RF, Tabas I, Pajvani UB. Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology. 2020;158(7):1913\u201328.","journal-title":"Gastroenterology"},{"issue":"5","key":"3832_CR44","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1136\/gutjnl-2023-329671","volume":"73","author":"M Kong","year":"2024","unstructured":"Kong M, Zhou J, Kang A, et al. Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis. Gut. 2024;73(5):810\u201324.","journal-title":"Gut"},{"issue":"1","key":"3832_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33800-0","volume":"13","author":"H Shen","year":"2022","unstructured":"Shen H, Huang X, Zhao Y, et al. The hippo pathway links adipocyte plasticity to adipose tissue fibrosis. Nat Commun. 2022;13(1):6030.","journal-title":"Nat Commun"},{"issue":"10","key":"3832_CR46","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/s41589-025-01901-8","volume":"21","author":"J Wei","year":"2025","unstructured":"Wei J, Cao Z, Li Q, et al. Nuclear ubiquitination permits Hippo\u2013YAP signal for liver development and tumorigenesis. Nat Chem Biol. 2025;21(10):1565\u201376.","journal-title":"Nat Chem Biol"},{"issue":"7350","key":"3832_CR47","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10137","volume":"474","author":"S Dupont","year":"2011","unstructured":"Dupont S, Morsut L, Aragona M, et al. Role of YAP\/TAZ in mechanotransduction. Nature. 2011;474(7350):179\u201383.","journal-title":"Nature"},{"issue":"1","key":"3832_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-025-00798-4","volume":"30","author":"J Wang","year":"2025","unstructured":"Wang J, Shen Z, Chen G, et al. YAP contributes to liver injury through mediating capillarization of liver sinusoidal endothelial cells via GATA6\/eNOS signaling. Cell Mol Biol Lett. 2025;30(1):119.","journal-title":"Cell Mol Biol Lett"},{"key":"3832_CR49","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jconrel.2024.10.012","volume":"376","author":"Y Yuan","year":"2024","unstructured":"Yuan Y, Li J, Chen M, et al. Nano-encapsulation of drugs to target hepatic stellate cells: toward precision treatments of liver fibrosis. J Control Release. 2024;376:318\u201336.","journal-title":"J Control Release"},{"issue":"5","key":"3832_CR50","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.7150\/thno.106597","volume":"15","author":"M Yan","year":"2025","unstructured":"Yan M, Cui Y, Xiang Q. Metabolism of hepatic stellate cells in chronic liver diseases: emerging molecular and therapeutic interventions. Theranostics. 2025;15(5):1715\u201340.","journal-title":"Theranostics"},{"key":"3832_CR51","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.colsurfb.2016.02.029","volume":"141","author":"T-L Pan","year":"2016","unstructured":"Pan T-L, Wang P-W, Hung C-F, Aljuffali IA, Dai Y-S, Fang J-Y. The impact of retinol loading and surface charge on the hepatic delivery of lipid nanoparticles. Colloids Surf B Biointerfaces. 2016;141:584\u201394.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3832_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115304","volume":"209","author":"Y Tang","year":"2024","unstructured":"Tang Y, Liu B, Zhang Y, Liu Y, Huang Y, Fan W. Interactions between nanoparticles and lymphatic systems: mechanisms and applications in drug delivery. Adv Drug Deliv Rev. 2024;209:115304.","journal-title":"Adv Drug Deliv Rev"},{"issue":"15","key":"3832_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20153812","volume":"20","author":"A-R Lee","year":"2019","unstructured":"Lee A-R, Nam K, Lee BJ, et al. Hepatic cellular distribution of silica nanoparticles by surface energy modification. Int J Mol Sci. 2019;20(15):3812.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3832_CR54","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s12072-019-09970-3","volume":"13","author":"JJ Alukal","year":"2019","unstructured":"Alukal JJ, Thuluvath PJ. Reversal of NASH fibrosis with pharmacotherapy. Hepatol Int. 2019;13(5):534\u201345.","journal-title":"Hepatol Int"},{"issue":"7","key":"3832_CR55","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1016\/S2665-9913(23)00299-0","volume":"6","author":"M Lanzillotta","year":"2024","unstructured":"Lanzillotta M, Culver E, Sharma A, et al. Fibrotic phenotype of IgG4-related disease. Lancet Rheumatol. 2024;6(7):e469\u201380.","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"3832_CR56","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1513\/AnnalsATS.202103-342OC","volume":"19","author":"M Ghazipura","year":"2022","unstructured":"Ghazipura M, Mammen MJ, Bissell BD, et al. Pirfenidone in progressive pulmonary fibrosis: a systematic review and meta-analysis. Ann Am Thorac Soc. 2022;19(6):1030\u20139.","journal-title":"Ann Am Thorac Soc"},{"issue":"36","key":"3832_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abg9241","volume":"7","author":"Y Xi","year":"2021","unstructured":"Xi Y, Li Y, Xu P, et al. The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1. Sci Adv. 2021;7(36):eabg9241.","journal-title":"Sci Adv"},{"issue":"22","key":"3832_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206798","volume":"10","author":"C Zheng","year":"2023","unstructured":"Zheng C, Zhang B, Li Y, et al. Donafenib and GSK-J4 synergistically induce ferroptosis in liver cancer by upregulating HMOX1 expression. Adv Sci. 2023;10(22):e2206798.","journal-title":"Adv Sci"},{"issue":"15","key":"3832_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202500101","volume":"14","author":"R Li","year":"2025","unstructured":"Li R, Tai Y, Zhang X, et al. Tissue-microenvironment-responsive self-assembling peptide nanoshells boost Pirfenidone efficacy in the treatment of liver fibrosis. Adv Healthc Mater. 2025;14(15):e2500101.","journal-title":"Adv Healthc Mater"},{"key":"3832_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103029","volume":"69","author":"Y Fu","year":"2024","unstructured":"Fu Y, Zhou X, Wang L, et al. Salvianolic acid B attenuates liver fibrosis by targeting Ecm1 and inhibiting hepatocyte ferroptosis. Redox Biol. 2024;69:103029.","journal-title":"Redox Biol"},{"issue":"8","key":"3832_CR61","doi-asserted-by":"publisher","first-page":"7621","DOI":"10.1007\/s12274-024-6725-z","volume":"17","author":"Y Yu","year":"2024","unstructured":"Yu Y, Zhang S, Xu Y, Shao H, Luo L. Oral delivery of ferroptosis inducers for effective treatment of hepatic fibrosis. Nano Res. 2024;17(8):7621\u201330.","journal-title":"Nano Res"},{"key":"3832_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2024.148976","volume":"482","author":"C-M Lai","year":"2024","unstructured":"Lai C-M, Xu J, Zhang B-C, He S-H, Shao J-W. A natural product-derived nanozyme regulator induced chemo-ferroptosis dual therapy in remodeling of the tumor immune microenvironment of hepatocellular carcinoma. Chem Eng J. 2024;482:148976.","journal-title":"Chem Eng J"},{"issue":"36","key":"3832_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202200858","volume":"18","author":"J Wang","year":"2022","unstructured":"Wang J, Huang D, Ren H, Shang L. Biomimic trained Immunity-MSCs delivery microcarriers for acute liver failure regeneration. Small. 2022;18(36):2200858.","journal-title":"Small"},{"issue":"4","key":"3832_CR64","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jhep.2018.06.008","volume":"69","author":"C Lebeaupin","year":"2018","unstructured":"Lebeaupin C, Vall\u00e9e D, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2018;69(4):927\u201347.","journal-title":"J Hepatol"},{"key":"3832_CR65","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.semcancer.2021.04.006","volume":"85","author":"CC Hsu","year":"2022","unstructured":"Hsu CC, Peng D, Cai Z, Lin HK. AMPK signaling and its targeting in cancer progression and treatment. Semin Cancer Biol. 2022;85:52\u201368.","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"3832_CR66","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1136\/gutjnl-2016-311408","volume":"65","author":"E Piccinin","year":"2016","unstructured":"Piccinin E, Moschetta A. Hepatic-specific PPAR\u03b1-FGF21 action in NAFLD. Gut. 2016;65(7):1075\u20136.","journal-title":"Gut"},{"issue":"41","key":"3832_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202402463","volume":"34","author":"S Yu","year":"2024","unstructured":"Yu S, Du J, Zhang Q, Li Z, Ge S, Ma B. Mitochondria-targeted polyphenol-cysteine nanoparticles regulating AMPK-mediated mitochondrial homeostasis for enhanced bone regeneration. Adv Funct Mater. 2024;34(41):2402463.","journal-title":"Adv Funct Mater"},{"issue":"4","key":"3832_CR68","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cmet.2018.09.015","volume":"28","author":"EC Fiedler","year":"2018","unstructured":"Fiedler EC, Shaw RJ. AMPK regulates the epigenome through phosphorylation of TET2. Cell Metab. 2018;28(4):534\u20136.","journal-title":"Cell Metab"},{"issue":"9","key":"3832_CR69","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1039\/D2EN01077A","volume":"10","author":"I Brandts","year":"2023","unstructured":"Brandts I, Sol\u00e0 R, Garcia-Ordo\u00f1ez M, et al. Polystyrene nanoplastics target lysosomes interfering with lipid metabolism through the PPAR system and affecting macrophage functionalization. Environ Sci Nano. 2023;10(9):2245\u201358. https:\/\/doi.org\/10.1039\/D2EN01077A.","journal-title":"Environ Sci Nano"},{"issue":"30","key":"3832_CR70","doi-asserted-by":"publisher","first-page":"34328","DOI":"10.1021\/acsami.2c05889","volume":"14","author":"Y Li","year":"2022","unstructured":"Li Y, Nie JJ, Yang Y, et al. Redox-unlockable nanoparticle-based MST1 delivery system to attenuate hepatic steatosis via the AMPK\/SREBP-1c signaling axis. ACS Appl Mater Interfaces. 2022;14(30):34328\u201341.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3832_CR71","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2019.06.023","volume":"307","author":"W Teng","year":"2019","unstructured":"Teng W, Zhao L, Yang S, et al. The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease. J Control Release. 2019;307:139\u201349.","journal-title":"J Control Release"},{"issue":"10","key":"3832_CR72","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.cmet.2023.07.011","volume":"35","author":"J Kuang","year":"2023","unstructured":"Kuang J, Wang J, Li Y, et al. Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis. Cell Metab. 2023;35(10):1752\u2013e17668.","journal-title":"Cell Metab"},{"issue":"3","key":"3832_CR73","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol. 2019;70(3):531\u201344.","journal-title":"J Hepatol"},{"issue":"624","key":"3832_CR74","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg8116","volume":"13","author":"XJ Zhang","year":"2021","unstructured":"Zhang XJ, Ji YX, Cheng X, et al. A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques. Sci Transl Med. 2021;13(624):eabg8116.","journal-title":"Sci Transl Med"},{"issue":"2","key":"3832_CR75","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/med.21991","volume":"44","author":"K Wang","year":"2024","unstructured":"Wang K, Zhang Y, Wang G, Hao H, Wang H. FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid. Med Res Rev. 2024;44(2):568\u201386.","journal-title":"Med Res Rev"},{"issue":"10","key":"3832_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308866","volume":"11","author":"H Lu","year":"2024","unstructured":"Lu H, Ban Z, Xiao K, et al. Hepatic-accumulated obeticholic acid and atorvastatin self-assembled nanocrystals potentiate ameliorative effects in treatment of metabolic-associated fatty liver disease. Adv Sci. 2024;11(10):e2308866.","journal-title":"Adv Sci"},{"issue":"2","key":"3832_CR77","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41575-020-00406-0","volume":"18","author":"MF Abdelmalek","year":"2021","unstructured":"Abdelmalek MF. Nonalcoholic fatty liver disease: another leap forward. Nat Rev Gastroenterol Hepatol. 2021;18(2):85\u20136.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"3832_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202405662","volume":"12","author":"J Wang","year":"2025","unstructured":"Wang J, Huang D, Ren H, Zhao Y. Biomimetic vascularized iPSC-hepatocyte spheroids for liver regeneration. Adv Sci (Weinh). 2025;12(6):e2405662.","journal-title":"Adv Sci (Weinh)"},{"key":"3832_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154368","volume":"106","author":"D Xu","year":"2022","unstructured":"Xu D, Zhao W, Feng Y, Wen X, Liu H, Ping J. Pentoxifylline attenuates nonalcoholic fatty liver by inhibiting hepatic macrophage polarization to the M1 phenotype. Phytomedicine. 2022;106:154368.","journal-title":"Phytomedicine"},{"issue":"2","key":"3832_CR80","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3109\/08982100903161456","volume":"20","author":"J Varshosaz","year":"2010","unstructured":"Varshosaz J, Minayian M, Moazen E. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J Liposome Res. 2010;20(2):115\u201323.","journal-title":"J Liposome Res"},{"issue":"4","key":"3832_CR81","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-020-01644-w","volume":"21","author":"AM Shailendrakumar","year":"2020","unstructured":"Shailendrakumar AM, Ghate VM, Kinra M, Lewis SA. Improved oral pharmacokinetics of Pentoxifylline with palm oil and Capmul\u00ae MCM containing self-nano-emulsifying drug delivery system. AAPS PharmSciTech. 2020;21(4):118.","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"3832_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25701-5","volume":"12","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Gunn N, Neff GW, et al. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nat Commun. 2021;12(1):5503.","journal-title":"Nat Commun"},{"issue":"3","key":"3832_CR83","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jhep.2024.08.031","volume":"82","author":"N Alkhouri","year":"2025","unstructured":"Alkhouri N, Beyer C, Shumbayawonda E, et al. Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH. J Hepatol. 2025;82(3):438\u201345.","journal-title":"J Hepatol"},{"issue":"12","key":"3832_CR84","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","volume":"20","author":"AG Singal","year":"2023","unstructured":"Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20(12):864\u201384.","journal-title":"Nat Rev Clin Oncol"},{"key":"3832_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2024.116270","volume":"255","author":"W Xue","year":"2024","unstructured":"Xue W, Wang L, Yi K, Sun L, Ren H, Bian F. Hepatocellular carcinoma biomarkers screening based on hydrogel photonic barcodes with tyramine deposition amplified ELISA. Biosens Bioelectron. 2024;255:116270.","journal-title":"Biosens Bioelectron"},{"issue":"1","key":"3832_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1047-6","volume":"18","author":"C Lu","year":"2019","unstructured":"Lu C, Rong D, Zhang B, et al. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol Cancer. 2019;18(1):130.","journal-title":"Mol Cancer"},{"issue":"1","key":"3832_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02210-9","volume":"24","author":"Y Liu","year":"2025","unstructured":"Liu Y, Xu L, Dou Y, He Y. AXL: shapers of tumor progression and immunosuppressive microenvironments. Mol Cancer. 2025;24(1):11.","journal-title":"Mol Cancer"},{"issue":"11","key":"3832_CR88","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1136\/gutjnl-2017-314098","volume":"67","author":"H Li","year":"2018","unstructured":"Li H, Zhai N, Wang Z, et al. Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection. Gut. 2018;67(11):2035\u201344.","journal-title":"Gut"},{"issue":"1","key":"3832_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00846-4","volume":"9","author":"V Akula","year":"2025","unstructured":"Akula V, Chen L, Acikgoz Y, et al. Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma. NPJ Precis Oncol. 2025;9(1):60.","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"3832_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061760","volume":"15","author":"S Kim","year":"2023","unstructured":"Kim S, Choi B, Kim Y, Shim G. Immune-modulating lipid nanomaterials for the delivery of biopharmaceuticals. Pharmaceutics. 2023;15(6):1760.","journal-title":"Pharmaceutics"},{"key":"3832_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2025.167894","volume":"523","author":"N Wang","year":"2025","unstructured":"Wang N, Zhu M, Yang S, et al. Dual-targeting pluripotential biomimetic nanovehicle modulates tumor immune microenvironment for potentiated cancer chemoimmunotherapy. Chem Eng J. 2025;523:167894.","journal-title":"Chem Eng J"},{"issue":"35","key":"3832_CR92","doi-asserted-by":"publisher","first-page":"32187","DOI":"10.1021\/jacs.5c11289","volume":"147","author":"J Jeon","year":"2025","unstructured":"Jeon J, Liu QJ, Woo H, et al. Computationally designed nanobinders as affinity ligands in diagnostic and therapeutic applications. J Am Chem Soc. 2025;147(35):32187\u201398.","journal-title":"J Am Chem Soc"},{"issue":"5","key":"3832_CR93","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.7150\/thno.69119","volume":"12","author":"Y Moon","year":"2022","unstructured":"Moon Y, Shim MK, Choi J, et al. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death. Theranostics. 2022;12(5):1999\u20132014.","journal-title":"Theranostics"},{"issue":"5","key":"3832_CR94","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293\u2013313.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"3832_CR95","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","volume":"15","author":"JM Llovet","year":"2018","unstructured":"Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599\u2013616.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"3832_CR96","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.scib.2023.12.006","volume":"69","author":"J Wang","year":"2024","unstructured":"Wang J, Zhang X, Chen H, Ren H, Zhou M, Zhao Y. Engineered stem cells by emerging biomedical stratagems. Sci Bull. 2024;69(2):248\u201379.","journal-title":"Sci Bull"},{"issue":"3","key":"3832_CR97","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","volume":"68","author":"N Fujiwara","year":"2018","unstructured":"Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68(3):526\u201349.","journal-title":"J Hepatol"},{"issue":"10064","key":"3832_CR98","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on Sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56\u201366.","journal-title":"Lancet"},{"issue":"8","key":"3832_CR99","volume":"8","author":"AK Nowak","year":"2020","unstructured":"Nowak AK, Findlay M, Culjak G, Stockler MR. Tamoxifen for hepatocellular carcinoma. Cochrane Database Syst Rev. 2020;8(8):Cd001024.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1\u20132","key":"3832_CR100","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ijpharm.2018.03.023","volume":"542","author":"MA Khan","year":"2018","unstructured":"Khan MA, Ali S, Venkatraman SS, Sohail MF, Ovais M, Raza A. Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes: an approach for improved oral pharmacokinetics of Sorafenib. Int J Pharm. 2018;542(1\u20132):196\u2013204.","journal-title":"Int J Pharm"},{"key":"3832_CR101","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1351046","volume":"2020","author":"H Ye","year":"2020","unstructured":"Ye H, Zhou L, Jin H, Chen Y, Cheng D, Jiang Y. Sorafenib-loaded long-circulating nanoliposomes for liver cancer therapy. BioMed Res Int. 2020;2020:1351046.","journal-title":"BioMed Res Int"},{"issue":"5","key":"3832_CR102","first-page":"6163","volume":"14","author":"X Sheng","year":"2017","unstructured":"Sheng X, Huang T, Qin J, et al. Preparation, pharmacokinetics, tissue distribution and antitumor effect of sorafenib-incorporating nanoparticles in vivo. Oncol Lett. 2017;14(5):6163\u20139.","journal-title":"Oncol Lett"},{"key":"3832_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.104978","volume":"137","author":"L Tunki","year":"2019","unstructured":"Tunki L, Kulhari H, Vadithe LN, et al. Modulating the site-specific oral delivery of Sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment. Eur J Pharm Sci. 2019;137:104978.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"3832_CR104","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1021\/acs.biomac.9b01419","volume":"21","author":"Y Li","year":"2020","unstructured":"Li Y, Wei J, Wei Y, et al. Apolipoprotein E peptide-guided disulfide-cross-linked micelles for targeted delivery of Sorafenib to hepatocellular carcinoma. Biomacromolecules. 2020;21(2):716\u201324.","journal-title":"Biomacromolecules"},{"issue":"11","key":"3832_CR105","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1007\/s13346-024-01530-z","volume":"14","author":"D Zaafar","year":"2024","unstructured":"Zaafar D, Khalil HMA, Elkhouly GE, et al. Preparation and characterization of Sorafenib nano-emulsion: impact on pharmacokinetics and toxicity; an in vitro and in vivo study. Drug Deliv Transl Res. 2024;14(11):3089\u2013111.","journal-title":"Drug Deliv Transl Res"},{"issue":"7","key":"3832_CR106","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"M He","year":"2019","unstructured":"He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953\u201360.","journal-title":"JAMA Oncol"},{"issue":"5","key":"3832_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04955-x","volume":"13","author":"H Liu","year":"2022","unstructured":"Liu H, Wang J, Ding Y, Shi X, Ren H. Antibiotic pretreatment attenuates liver ischemia-reperfusion injury by farnesoid X receptor activation. Cell Death Dis. 2022;13(5):484.","journal-title":"Cell Death Dis"},{"issue":"2","key":"3832_CR108","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.apsb.2021.09.019","volume":"12","author":"D Du","year":"2022","unstructured":"Du D, Liu C, Qin M, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sin B. 2022;12(2):558\u201380.","journal-title":"Acta Pharm Sin B"},{"key":"3832_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104400","volume":"148","author":"X Gao","year":"2019","unstructured":"Gao X, Wei M, Shan W, et al. An oral 2-hydroxypropyl-\u03b2-cyclodextrin-loaded spirooxindole-pyrrolizidine derivative restores p53 activity via targeting MDM2 and JNK1\/2 in hepatocellular carcinoma. Pharmacol Res. 2019;148:104400.","journal-title":"Pharmacol Res"},{"issue":"6","key":"3832_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05879-w","volume":"14","author":"H Ren","year":"2023","unstructured":"Ren H, Chen Y, Zhu Z, et al. FOXO1 regulates Th17 cell-mediated hepatocellular carcinoma recurrence after hepatic ischemia-reperfusion injury. Cell Death Dis. 2023;14(6):367.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3832_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02808-7","volume":"22","author":"L Wang","year":"2024","unstructured":"Wang L, Tong L, Xiong Z, et al. Ferroptosis-inducing nanomedicine and targeted short peptide for synergistic treatment of hepatocellular carcinoma. J Nanobiotechnol. 2024;22(1):533.","journal-title":"J Nanobiotechnol"},{"issue":"11","key":"3832_CR112","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1038\/mt.2015.147","volume":"23","author":"JY Liu","year":"2015","unstructured":"Liu JY, Chiang T, Liu CH, et al. Delivery of siRNA using CXCR4-targeted nanoparticles modulates tumor microenvironment and achieves a potent antitumor response in liver cancer. Mol Ther. 2015;23(11):1772\u201382.","journal-title":"Mol Ther"},{"issue":"Pt 3","key":"3832_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.134369","volume":"277","author":"G Wen","year":"2024","unstructured":"Wen G, Xue L, Qiu M, Qiu J, Zhu X, Ren H. Biohybrid hydrogel inhibiting \u03b2-klotho\/HDAC3 axis for hepatocellular carcinoma treatment. Int J Biol Macromol. 2024;277(Pt 3):134369.","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"3832_CR114","doi-asserted-by":"publisher","DOI":"10.1002\/SMMD.20220029","volume":"2","author":"Z Zhu","year":"2023","unstructured":"Zhu Z, Chen Y, Qin X, Liu S, Wang J, Ren H. Multidimensional landscape of non-alcoholic fatty liver disease-related disease spectrum uncovered by big omics data: profiling evidence and new perspectives. Smart Medicine. 2023;2(2):e20220029.","journal-title":"Smart Medicine"},{"issue":"1","key":"3832_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03378-y","volume":"23","author":"H Zheng","year":"2025","unstructured":"Zheng H, Chen Y, Luo W, et al. Integration of active ingredients from traditional Chinese medicine with nano-delivery systems for tumor immunotherapy. J Nanobiotechnol. 2025;23(1):357.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"3832_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01777-4","volume":"10","author":"Y Chen","year":"2024","unstructured":"Chen Y, Zhu Z, Wu X, Li H, Guan W, Ren H. CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma. Cell Death Discov. 2024;10(1):37.","journal-title":"Cell Death Discov"},{"key":"3832_CR117","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jconrel.2020.12.036","volume":"330","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Liang J, Gao C, et al. Multifunctional ginsenoside Rg3-based liposomes for glioma targeting therapy. J Control Release. 2021;330:641\u201357.","journal-title":"J Control Release"},{"issue":"11","key":"3832_CR118","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.7150\/thno.54822","volume":"11","author":"FH Kong","year":"2021","unstructured":"Kong FH, Ye QF, Miao XY, et al. Current status of Sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics. 2021;11(11):5464\u201390.","journal-title":"Theranostics"},{"issue":"8","key":"3832_CR119","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s11548-025-03423-z","volume":"20","author":"N Varble","year":"2025","unstructured":"Varble N, Li M, Saccenti L, et al. Estimation of tumor coverage after RF ablation of hepatocellular carcinoma using single 2D image slices. Int J Comput Assist Radiol Surg. 2025;20(8):1653\u201363.","journal-title":"Int J Comput Assist Radiol Surg"},{"issue":"1","key":"3832_CR120","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02193-1","volume":"40","author":"R Cuciniello","year":"2021","unstructured":"Cuciniello R, Filosa S, Crispi S. Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics. J Exp Clin Cancer Res. 2021;40(1):383.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"3832_CR121","first-page":"147","volume":"33","author":"Y Xu","year":"2023","unstructured":"Xu Y, Wang J, Ren H, et al. Human endoderm stem cells reverse inflammation-related acute liver failure through Cystatin SN-mediated Inhibition of interferon signaling. Cell Res. 2023;33(2):147\u201364.","journal-title":"Cell Res"},{"issue":"12","key":"3832_CR122","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.tem.2023.09.002","volume":"34","author":"P Luo","year":"2023","unstructured":"Luo P, Li S, Jing W, Tu J, Long X. N6-methyladenosine RNA modification in nonalcoholic fatty liver disease. Trends Endocrinol Metab. 2023;34(12):838\u201348.","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"3832_CR123","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/hep.32181","volume":"75","author":"EJ Lawitz","year":"2022","unstructured":"Lawitz EJ, Shevell DE, Tirucherai GS, et al. BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial. Hepatology. 2022;75(4):912\u201323.","journal-title":"Hepatology"},{"key":"3832_CR124","unstructured":"A Proof-of. -Concept and Dose-Ranging study investigating the efficacy and safety of HTD1801 in adults with NASH and T2DM. National Library of Medicine (US). 2025. https:\/\/clinicaltrials.gov\/study\/NCT03656744."},{"key":"3832_CR125","unstructured":"Phase A. 2, Randomized, Double-blind, Placebo-controlled Study With Additional Open-label, Single-blind and Placebo-controlled Cohorts to Assess the Safety, Tolerability, and Efficacy of NGM282 in Patients With Nonalcoholic Steatohepatitis. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT02443116"},{"key":"3832_CR126","unstructured":"Phase A, Randomized III, Blind D. Dummy-Controlled Study of ThermoDox\u00ae (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time\u2009\u2265\u200945 Minutes for Solitary Lesions\u2009\u2265\u20093\u00a0cm to \u2264\u20097\u00a0cm. National Library of Medicine (US). 2014. https:\/\/clinicaltrials.gov\/study\/NCT02112656."},{"key":"3832_CR127","doi-asserted-by":"publisher","unstructured":"Chen L, Guan Y, Wang S, Han X, Guo F, Wang Y. Engineered nanoplatforms for brain-targeted co-delivery of phytochemicals in Alzheimer\u2019s disease: Rational design, blood-brain barrier penetration, and multi-target therapeutic synergy. Neurotherapeutics. 2025:e00722 510. https:\/\/doi.org\/10.1016\/j.ccr.2024.215841.","DOI":"10.1016\/j.ccr.2024.215841"},{"key":"3832_CR128","unstructured":"Phase 1b\/2. Multicenter, dose escalation trial to determine the Safety, Tolerance, maximum tolerated dose and recommended phase 2 dose of DCR-MYC, a lipid nanoparticle (LNP)-Formulated small inhibitory RNA (siRNA) oligonucleotide targeting MYC, in patients with hepatocellular carcinoma (HCC). National Library of Medicine (US). 2024. https:\/\/clinicaltrials.gov\/study\/NCT02314052."},{"key":"3832_CR129","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.addr.2019.01.005","volume":"138","author":"SM Dadfar","year":"2019","unstructured":"Dadfar SM, Roemhild K, Drude NI, et al. Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev. 2019;138:302\u201325.","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"3832_CR130","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/17425247.2024.2375400","volume":"21","author":"Y He","year":"2024","unstructured":"He Y, Wang Y, Wang L, Jiang W, Wilhelm S. Understanding nanoparticle-liver interactions in nanomedicine. Expert Opin Drug Deliv. 2024;21(6):829\u201343.","journal-title":"Expert Opin Drug Deliv"},{"issue":"11","key":"3832_CR131","doi-asserted-by":"publisher","first-page":"10049","DOI":"10.1021\/acsnano.6b04695","volume":"10","author":"Z Chen","year":"2016","unstructured":"Chen Z, Zhao P, Luo Z, et al. Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy. ACS Nano. 2016;10(11):10049\u201357.","journal-title":"ACS Nano"},{"issue":"6","key":"3832_CR132","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1021\/acsnano.3c06107","volume":"18","author":"J Shinn","year":"2024","unstructured":"Shinn J, Park S, Lee S, et al. Antioxidative hyaluronic acid-bilirubin nanomedicine targeting activated hepatic stellate cells for anti-hepatic-fibrosis therapy. ACS Nano. 2024;18(6):4704\u201316.","journal-title":"ACS Nano"},{"key":"3832_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173832","volume":"893","author":"D Ezhilarasan","year":"2021","unstructured":"Ezhilarasan D. Advantages and challenges in nanomedicines for chronic liver diseases: a hepatologist\u2019s perspectives. Eur J Pharmacol. 2021;893:173832.","journal-title":"Eur J Pharmacol"},{"issue":"17","key":"3832_CR134","doi-asserted-by":"publisher","first-page":"7921","DOI":"10.7150\/thno.49577","volume":"10","author":"Y Shi","year":"2020","unstructured":"Shi Y, van der Meel R, Chen X, Lammers T. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 2020;10(17):7921\u20134.","journal-title":"Theranostics"},{"issue":"3","key":"3832_CR135","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2174\/1381612827666211007150414","volume":"28","author":"RK Kankala","year":"2022","unstructured":"Kankala RK. Organic- or Inorganic-based nanomaterials: opportunities and challenges in the selection for biomedicines. Curr Pharm Des. 2022;28(3):208\u201315.","journal-title":"Curr Pharm Des"},{"key":"3832_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115481","volume":"216","author":"L Dykman","year":"2025","unstructured":"Dykman L, Khlebtsov B, Khlebtsov N. Drug delivery using gold nanoparticles. Adv Drug Deliv Rev. 2025;216:115481.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"3832_CR137","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201902634","volume":"30","author":"M Manzano","year":"2020","unstructured":"Manzano M, Vallet-Reg\u00ed M. Mesoporous silica nanoparticles for drug delivery. Adv Funct Mater. 2020;30(2):1902634.","journal-title":"Adv Funct Mater"},{"issue":"6","key":"3832_CR138","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s10311-020-01061-2","volume":"18","author":"J Meena","year":"2020","unstructured":"Meena J, Gupta A, Ahuja R, Singh M, Bhaskar S, Panda AK. Inorganic nanoparticles for natural product delivery: a review. Environ Chem Lett. 2020;18(6):2107\u201318.","journal-title":"Environ Chem Lett"},{"issue":"10","key":"3832_CR139","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41557-024-01584-z","volume":"16","author":"CP Pilkington","year":"2024","unstructured":"Pilkington CP, Gispert I, Chui SY, Seddon JM, Elani Y. Engineering a nanoscale liposome-in-liposome for in situ biochemical synthesis and multi-stage release. Nat Chem. 2024;16(10):1612\u201320.","journal-title":"Nat Chem"},{"issue":"6","key":"3832_CR140","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41565-024-01620-6","volume":"19","author":"MM Rahman","year":"2024","unstructured":"Rahman MM, Wang J, Wang G, et al. Chimeric nanobody-decorated liposomes by self-assembly. Nat Nanotechnol. 2024;19(6):818\u201324.","journal-title":"Nat Nanotechnol"},{"issue":"32","key":"3832_CR141","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202204791","volume":"32","author":"M Chang","year":"2022","unstructured":"Chang M, Dong C, Huang H, Ding L, Feng W, Chen Y. Nanobiomimetic medicine. Adv Funct Mater. 2022;32(32):2204791.","journal-title":"Adv Funct Mater"},{"issue":"15","key":"3832_CR142","doi-asserted-by":"publisher","first-page":"9243","DOI":"10.1021\/acs.chemrev.0c01176","volume":"121","author":"WR Algar","year":"2021","unstructured":"Algar WR, Massey M, Rees K, et al. Photoluminescent nanoparticles for chemical and biological analysis and imaging. Chem Rev. 2021;121(15):9243\u2013358.","journal-title":"Chem Rev"},{"issue":"12","key":"3832_CR143","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1021\/acs.accounts.3c00151","volume":"56","author":"G Lin","year":"2023","unstructured":"Lin G, Zhang M. Ligand chemistry in antitumor theranostic nanoparticles. Acc Chem Res. 2023;56(12):1578\u201390.","journal-title":"Acc Chem Res"},{"issue":"10","key":"3832_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202300082","volume":"6","author":"S Zanganeh","year":"2023","unstructured":"Zanganeh S, Doroudian M, Nowzari ZR, et al. Viral nanoparticles-mediated delivery of therapeutic cargo. Adv Ther. 2023;6(10):2300082.","journal-title":"Adv Ther"},{"issue":"1","key":"3832_CR145","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01698-x","volume":"20","author":"L Tian","year":"2022","unstructured":"Tian L, Li X, Ji H, et al. Melanin-like nanoparticles: advances in surface modification and tumour photothermal therapy. J Nanobiotechnol. 2022;20(1):485.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"3832_CR146","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1515\/ntrev-2023-0218","volume":"13","author":"AH Maboudi","year":"2024","unstructured":"Maboudi AH, Lotfipour MH, Rasouli M, et al. Micelle-based nanoparticles with stimuli-responsive properties for drug delivery. Nanotechnol Rev. 2024;13(1):2253\u201369. https:\/\/doi.org\/10.1515\/ntrev-2023-0218.","journal-title":"Nanotechnol Rev"},{"key":"3832_CR147","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2020.07.002","volume":"154\u2013155","author":"S Shah","year":"2020","unstructured":"Shah S, Dhawan V, Holm R, Nagarsenker MS, Perrie Y, Liposomes. Advancements and innovation in the manufacturing process. Adv Drug Deliv Rev. 2020;154\u2013155:102\u201322.","journal-title":"Adv Drug Deliv Rev"},{"key":"3832_CR148","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jconrel.2020.09.055","volume":"329","author":"JJ Sonju","year":"2021","unstructured":"Sonju JJ, Dahal A, Singh SS, Jois SD. Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment. J Control Release. 2021;329:624\u201344.","journal-title":"J Control Release"},{"key":"3832_CR149","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addr.2020.06.017","volume":"154\u2013155","author":"R B\u00f6ttger","year":"2020","unstructured":"B\u00f6ttger R, Pauli G, Chao PH, Al Fayez N, Hohenwarter L, Li SD. Lipid-based nanoparticle technologies for liver targeting. Adv Drug Deliv Rev. 2020;154\u2013155:79\u2013101.","journal-title":"Adv Drug Deliv Rev"},{"issue":"16","key":"3832_CR150","doi-asserted-by":"publisher","first-page":"e2201095","DOI":"10.1002\/adma.202201095","volume":"34","author":"R Pattipeiluhu","year":"2022","unstructured":"Pattipeiluhu R, Arias-Alpizar G, Basha G, et al. Anionic lipid nanoparticles preferentially deliver mRNA to the hepatic reticuloendothelial system. Adv Mater. 2022;34(16):e2201095.","journal-title":"Adv Mater"},{"issue":"1","key":"3832_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49332-8","volume":"15","author":"R Smith","year":"2024","unstructured":"Smith R, Rizvi F, Everton E, et al. Transient growth factor expression via mRNA in lipid nanoparticles promotes hepatocyte cell therapy in mice. Nat Commun. 2024;15(1):5010.","journal-title":"Nat Commun"},{"issue":"1","key":"3832_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20903-3","volume":"12","author":"F Rizvi","year":"2021","unstructured":"Rizvi F, Everton E, Smith AR, et al. Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA. Nat Commun. 2021;12(1):613.","journal-title":"Nat Commun"},{"key":"3832_CR153","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jconrel.2024.07.011","volume":"373","author":"Y Lyu","year":"2024","unstructured":"Lyu Y, Yang X, Yang L, et al. Lipid nanoparticle-mediated hepatocyte delivery of siRNA and silibinin in metabolic dysfunction-associated steatotic liver disease. J Control Release. 2024;373:385\u201398.","journal-title":"J Control Release"},{"issue":"1","key":"3832_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35637-z","volume":"14","author":"X Han","year":"2023","unstructured":"Han X, Gong N, Xue L, et al. Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis. Nat Commun. 2023;14(1):75.","journal-title":"Nat Commun"},{"issue":"2","key":"3832_CR155","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3350\/cmh.2024.0854","volume":"31","author":"L Li","year":"2024","unstructured":"Li L, Liu Y, Wang K et al. Stem cell exosomes: new hope and future potential for relieving liver fibrosis. Clin Mol Hepatol. 2024;31(2):333\u201349. https:\/\/doi.org\/10.3350\/cmh.2024.0854.","journal-title":"Clin Mol Hepatol"},{"key":"3832_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216220","volume":"565","author":"DN Moholkar","year":"2023","unstructured":"Moholkar DN, Kandimalla R, Gupta RC, Aqil F. Advances in lipid-based carriers for cancer therapeutics: liposomes, exosomes and hybrid exosomes. Cancer Lett. 2023;565:216220.","journal-title":"Cancer Lett"},{"issue":"17","key":"3832_CR157","doi-asserted-by":"publisher","first-page":"16770","DOI":"10.1021\/acsnano.3c03456","volume":"17","author":"T Zhu","year":"2023","unstructured":"Zhu T, Chen Z, Jiang G, Huang X. Sequential targeting hybrid nanovesicles composed of chimeric antigen receptor T-cell-derived exosomes and liposomes for enhanced cancer immunochemotherapy. ACS Nano. 2023;17(17):16770\u201386.","journal-title":"ACS Nano"},{"issue":"1","key":"3832_CR158","doi-asserted-by":"publisher","first-page":"18397","DOI":"10.3402\/jev.v1i0.18397","volume":"1","author":"A Bobrie","year":"2012","unstructured":"Bobrie A, Colombo M, Krumeich S, Raposo G, Th\u00e9ry C. Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation. J Extracell Vesicles. 2012;1(1):18397. https:\/\/doi.org\/10.3402\/jev.v1i0.18397.","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"3832_CR159","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02634-x","volume":"22","author":"Z Iqbal","year":"2024","unstructured":"Iqbal Z, Rehman K, Mahmood A, et al. Exosome for mRNA delivery: strategies and therapeutic applications. J Nanobiotechnol. 2024;22(1):395.","journal-title":"J Nanobiotechnol"},{"key":"3832_CR160","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jconrel.2020.10.020","volume":"329","author":"J Wang","year":"2021","unstructured":"Wang J, Chen D, Ho EA. Challenges in the development and establishment of exosome-based drug delivery systems. J Control Release. 2021;329:894\u2013906.","journal-title":"J Control Release"},{"issue":"3","key":"3832_CR161","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1039\/D1BM01663F","volume":"10","author":"K Ji","year":"2022","unstructured":"Ji K, Fan M, Huang D, et al. Clodronate-nintedanib-loaded exosome-liposome hybridization enhances the liver fibrosis therapy by inhibiting Kupffer cell activity. Biomater Sci. 2022;10(3):702\u201313.","journal-title":"Biomater Sci"},{"key":"3832_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103565","volume":"169","author":"NA Hanjani","year":"2022","unstructured":"Hanjani NA, Esmaelizad N, Zanganeh S, et al. Emerging role of exosomes as biomarkers in cancer treatment and diagnosis. Crit Rev Oncol Hematol. 2022;169:103565.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"3832_CR163","doi-asserted-by":"publisher","first-page":"116","DOI":"10.7150\/thno.88061","volume":"14","author":"S Liu","year":"2024","unstructured":"Liu S, Xiao X, Zhang L, et al. Reprogramming exosomes to escape from immune surveillance for mitochondrial protection in hepatic ischemia-reperfusion injury. Theranostics. 2024;14(1):116\u201332.","journal-title":"Theranostics"},{"issue":"1","key":"3832_CR164","doi-asserted-by":"publisher","DOI":"10.1186\/s40580-024-00423-8","volume":"11","author":"S Ding","year":"2024","unstructured":"Ding S, Kim YJ, Huang KY, Um D, Jung Y, Kong H. Delivery-mediated exosomal therapeutics in ischemia-reperfusion injury: advances, mechanisms, and future directions. Nano Convergence. 2024;11(1):18.","journal-title":"Nano Convergence"},{"issue":"1","key":"3832_CR165","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00359-5","volume":"5","author":"E Yang","year":"2020","unstructured":"Yang E, Wang X, Gong Z, Yu M, Wu H, Zhang D. Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression. Signal Transduct Target Ther. 2020;5(1):242.","journal-title":"Signal Transduct Target Ther"},{"key":"3832_CR166","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.jconrel.2022.12.027","volume":"353","author":"J Mondal","year":"2023","unstructured":"Mondal J, Pillarisetti S, Junnuthula V, et al. Hybrid exosomes, exosome-like nanovesicles and engineered exosomes for therapeutic applications. J Control Release. 2023;353:1127\u201349.","journal-title":"J Control Release"},{"issue":"1","key":"3832_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17418-8","volume":"11","author":"S-H Kang","year":"2020","unstructured":"Kang S-H, Lee W-j, An J-H, et al. Prediction-based highly sensitive CRISPR off-target validation using target-specific DNA enrichment. Nat Commun. 2020;11(1):3596.","journal-title":"Nat Commun"},{"issue":"1","key":"3832_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01382-y","volume":"8","author":"M Zhang","year":"2023","unstructured":"Zhang M, Hu S, Liu L, et al. Engineered exosomes from different sources for cancer-targeted therapy. Signal Transduct Target Ther. 2023;8(1):124.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3832_CR169","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2023.2226367","volume":"30","author":"X Lu","year":"2023","unstructured":"Lu X, Sun Y, Han M, et al. Triptorelin nanoparticle-loaded microneedles for use in assisted reproductive technology. Drug Deliv. 2023;30(1):2226367.","journal-title":"Drug Deliv"},{"key":"3832_CR170","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jconrel.2021.08.036","volume":"338","author":"S Khan","year":"2021","unstructured":"Khan S, Hasan A, Attar F, et al. Diagnostic and drug release systems based on microneedle arrays in breast cancer therapy. J Control Release. 2021;338:341\u201357.","journal-title":"J Control Release"},{"key":"3832_CR171","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.jconrel.2024.10.042","volume":"376","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang Q, Zhong Q, et al. Immunomodulatory microneedle patch for enhanced ferroptosis and immunogenic cell death in postoperative tumor therapy. J Control Release. 2024;376:766\u201376.","journal-title":"J Control Release"},{"key":"3832_CR172","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jconrel.2021.10.001","volume":"339","author":"K Peng","year":"2021","unstructured":"Peng K, Vora LK, Tekko IA, et al. Dissolving microneedle patches loaded with amphotericin B microparticles for localised and sustained intradermal delivery: potential for enhanced treatment of cutaneous fungal infections. J Control Release. 2021;339:361\u201380.","journal-title":"J Control Release"},{"key":"3832_CR173","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106711","volume":"195","author":"S Shen","year":"2024","unstructured":"Shen S, Zheng X, Dong X, et al. Methotrexate-loaded hyaluronan-modified liposomes integrated into dissolving microneedles for the treatment of psoriasis. Eur J Pharm Sci. 2024;195:106711.","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"3832_CR174","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/17425247.2022.2119220","volume":"19","author":"F Sabbagh","year":"2022","unstructured":"Sabbagh F, Kim BS. Microneedles for transdermal drug delivery using clay-based composites. Expert Opin Drug Deliv. 2022;19(9):1099\u2013113.","journal-title":"Expert Opin Drug Deliv"},{"key":"3832_CR175","first-page":"314","volume":"23","author":"R Haghniaz","year":"2023","unstructured":"Haghniaz R, Kim HJ, Montazerian H, et al. Tissue adhesive hemostatic microneedle arrays for rapid hemorrhage treatment. Bioact Mater. 2023;23:314\u201327.","journal-title":"Bioact Mater"},{"key":"3832_CR176","doi-asserted-by":"publisher","first-page":"113018","DOI":"10.1016\/j.colsurfb.2022.113018","volume":"222","author":"D Elim","year":"2023","unstructured":"Elim D, Fitri AMN, Mahfud MAS, et al. Hydrogel forming microneedle-mediated transdermal delivery of sildenafil citrate from polyethylene glycol reservoir: an ex vivo proof of concept study. Colloids Surf B Biointerfaces. 2023;222:113018.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3832_CR177","unstructured":"Sun Y, Miao D, Zeng Z et al. Recent Advances in Micro\/Nanoneedle Arrays Mediated Intracellular Delivery of Biomacromolecules In Vitro and In Vivo. Advanced Functional Materials. n\/a(n\/a):2422234."},{"key":"3832_CR178","first-page":"1","volume":"51","author":"Y Yang","year":"2025","unstructured":"Yang Y, Sun H, Sun X, et al. From mechanism to applications: advanced microneedles for clinical medicine. Bioact Mater. 2025;51:1\u201345.","journal-title":"Bioact Mater"},{"issue":"31","key":"3832_CR179","doi-asserted-by":"publisher","first-page":"e2309940","DOI":"10.1002\/advs.202309940","volume":"11","author":"Y Xu","year":"2024","unstructured":"Xu Y, Zhang Y, Tian H, et al. Smart microneedle arrays integrating Cell-Free therapy and nanocatalysis to treat liver fibrosis. Adv Sci (Weinh). 2024;11(31):e2309940.","journal-title":"Adv Sci (Weinh)"},{"issue":"28","key":"3832_CR180","doi-asserted-by":"publisher","first-page":"6595","DOI":"10.1039\/D3TB00708A","volume":"11","author":"E Ju","year":"2023","unstructured":"Ju E, Peng M, Xu Y, et al. Nanozyme-integrated microneedle patch for enhanced therapy of cutaneous squamous cell carcinoma by breaking the gap between H2O2 self-supplying chemodynamic therapy and photothermal therapy. J Mater Chem B. 2023;11(28):6595\u2013602.","journal-title":"J Mater Chem B"},{"issue":"28","key":"3832_CR181","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300822","volume":"10","author":"S Wang","year":"2023","unstructured":"Wang S, Wang Y, Lin L, et al. Layer-specific BTX-A delivery to the gastric muscularis achieves effective weight control and metabolic improvement. Adv Sci. 2023;10(28):e2300822.","journal-title":"Adv Sci"},{"key":"3832_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41378-023-00544-w","volume":"9","author":"S Li","year":"2023","unstructured":"Li S, Li C, Khan MI, et al. Microneedle array facilitates hepatic sinusoid construction in a large-scale liver-acinus-chip microsystem. Microsyst Nanoeng. 2023;9:75.","journal-title":"Microsyst Nanoeng"},{"issue":"32","key":"3832_CR183","doi-asserted-by":"publisher","first-page":"38745","DOI":"10.1021\/acsami.1c11179","volume":"13","author":"AD Permana","year":"2021","unstructured":"Permana AD, Paredes AJ, Zanutto FV, et al. Albendazole Nanocrystal-Based dissolving microneedles with improved Pharmacokinetic performance for enhanced treatment of cystic echinococcosis. ACS Appl Mater Interfaces. 2021;13(32):38745\u201360.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"10","key":"3832_CR184","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.scib.2024.02.030","volume":"69","author":"J Wang","year":"2024","unstructured":"Wang J, Huang D, Chen H, Zhao Y. Biomimetic hepatic lobules from three-dimensional imprinted cell sheets. Sci Bull. 2024;69(10):1448\u201357.","journal-title":"Sci Bull"},{"issue":"2","key":"3832_CR185","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41440-023-01466-w","volume":"47","author":"BA Jana","year":"2024","unstructured":"Jana BA, Shivhare P, Srivastava R. Gelatin\u2013PVP dissolving microneedle-mediated therapy for controlled delivery of Nifedipine for rapid antihypertension treatment. Hypertens Res. 2024;47(2):427\u201334.","journal-title":"Hypertens Res"},{"issue":"1","key":"3832_CR186","doi-asserted-by":"publisher","DOI":"10.1038\/s41378-025-01005-2","volume":"11","author":"S Sarker","year":"2025","unstructured":"Sarker S, Wen Z, Acevedo R, et al. 3D nanoprinting of embryo microinjection needles with anti-clogging features. Microsyst Nanoeng. 2025;11(1):171.","journal-title":"Microsyst Nanoeng"},{"key":"3832_CR187","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.ijbiomac.2022.11.165","volume":"225","author":"F Eftekhari-Pournigjeh","year":"2023","unstructured":"Eftekhari-Pournigjeh F, Saeed M, Rajabi S, Tamimi M, Pezeshki-Modaress M. Three-dimensional biomimetic reinforced chitosan\/gelatin composite scaffolds containing PLA nano\/microfibers for soft tissue engineering application. Int J Biol Macromol. 2023;225:1028\u201337.","journal-title":"Int J Biol Macromol"},{"key":"3832_CR188","first-page":"98","volume":"30","author":"X Dong","year":"2023","unstructured":"Dong X, Yang Y, Bao Z, et al. Micro-nanofiber composite biomimetic conduits promote long-gap peripheral nerve regeneration in canine models. Bioact Mater. 2023;30:98\u2013115.","journal-title":"Bioact Mater"},{"issue":"Pt 3","key":"3832_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.134936","volume":"278","author":"SA Jamali","year":"2024","unstructured":"Jamali SA, Mohammadi M, Saeed M, Haramshahi SMA, Shahmahmoudi Z, Pezeshki-Modaress M. Biomimetic fiber\/hydrogel composite scaffolds based on chitosan hydrogel and surface modified PCL chopped-microfibers. Int J Biol Macromol. 2024;278(Pt 3):134936.","journal-title":"Int J Biol Macromol"},{"key":"3832_CR190","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.610249","volume":"8","author":"B Lu","year":"2020","unstructured":"Lu B, Li M, Fang Y, Liu Z, Zhang T, Xiong Z. Rapid fabrication of cell-laden microfibers for construction of aligned biomimetic tissue. Front Bioeng Biotechnol. 2020;8:610249.","journal-title":"Front Bioeng Biotechnol"},{"key":"3832_CR191","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2022.952675","volume":"10","author":"F Farjadian","year":"2022","unstructured":"Farjadian F, Ghasemi S, Akbarian M, Hoseini-Ghahfarokhi M, Moghoofei M, Doroudian M. Physically stimulus-responsive nanoparticles for therapy and diagnosis. Front Chem. 2022;10:952675.","journal-title":"Front Chem"},{"issue":"18","key":"3832_CR192","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300127","volume":"10","author":"Y Liang","year":"2023","unstructured":"Liang Y, Wang J, Xu C, et al. Remodeling collagen microenvironment in liver using a biomimetic nano-regulator for reversal of liver fibrosis. Adv Sci. 2023;10(18):e2300127.","journal-title":"Adv Sci"},{"issue":"10","key":"3832_CR193","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/pharmaceutics16101303","volume":"16","author":"J Li","year":"2024","unstructured":"Li J, Yin M, Tian M, Fang J, Xu H. Stiff-soft hybrid biomimetic nano-emulsion for targeted liver delivery and treatment of early nonalcoholic fatty liver disease. Pharmaceutics. 2024;16(10): 1303. https:\/\/doi.org\/10.3390\/pharmaceutics16101303.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3832_CR194","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/10717544.2021.1949075","volume":"28","author":"Q Yao","year":"2021","unstructured":"Yao Q, Yang G, Wang H, et al. Aging erythrocyte membranes as biomimetic nanometer carriers of liver-targeting chromium poisoning treatment. Drug Deliv. 2021;28(1):1455\u201365.","journal-title":"Drug Deliv"},{"issue":"3","key":"3832_CR195","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s42765-024-00395-8","volume":"6","author":"X Liu","year":"2024","unstructured":"Liu X, Yao X, OuYang Q, Oliveira AL, Yan L, Zhang Y. Nanofiber scaffold-based tissue engineering for the treatment of acute liver failure. Adv Fiber Mater. 2024;6(3):686\u2013712.","journal-title":"Adv Fiber Mater"},{"key":"3832_CR196","doi-asserted-by":"publisher","DOI":"10.34133\/research.0634","volume":"8","author":"J Wang","year":"2025","unstructured":"Wang J, Huang D, Ren H, Zhao Y. Bioinspired spatially ordered multicellular lobules for liver regeneration. Research. 2025;8:0634.","journal-title":"Research"},{"key":"3832_CR197","unstructured":"Song T, Shen Q, Cheng Y et al. Mechanically Tunable Hydrogel Microfibers for Biomimetic Tumor Drug Testing. Advanced Functional Materials. n\/a(n\/a):2502840."},{"key":"3832_CR198","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2023.144901","volume":"472","author":"Y Chen","year":"2023","unstructured":"Chen Y, Guo J, Wu X, et al. Microfluidic spinning of natural origin microfibers for breast tumor postsurgical treatment. Chem Eng J. 2023;472:144901.","journal-title":"Chem Eng J"},{"issue":"3","key":"3832_CR199","doi-asserted-by":"publisher","first-page":"e2302170","DOI":"10.1002\/adhm.202302170","volume":"13","author":"Y Wang","year":"2024","unstructured":"Wang Y, Guo J, Luo Z, et al. Biopolymer-Assembled porous hydrogel microfibers from microfluidic spinning for wound healing. Adv Healthc Mater. 2024;13(3):e2302170.","journal-title":"Adv Healthc Mater"},{"key":"3832_CR200","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2024.158133","volume":"502","author":"S Song","year":"2024","unstructured":"Song S, Guo J, Kong B, et al. Black phosphorus-loaded anisotropic nanofiber sponges for random skin flaps regeneration. Chem Eng J. 2024;502:158133.","journal-title":"Chem Eng J"},{"issue":"37","key":"3832_CR201","doi-asserted-by":"publisher","first-page":"41712","DOI":"10.1021\/acsami.2c10322","volume":"14","author":"L Wang","year":"2022","unstructured":"Wang L, Liu Q, Hu X, et al. Enhanced oral absorption and liver distribution of polymeric nanoparticles through traveling the enterohepatic circulation pathways of bile acid. ACS Appl Mater Interfaces. 2022;14(37):41712\u201325.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3832_CR202","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2024.173458","volume":"935","author":"X Chen","year":"2024","unstructured":"Chen X, Xuan Y, Chen Y, et al. Polystyrene nanoplastics induce intestinal and hepatic inflammation through activation of NF-\u03baB\/NLRP3 pathways and related gut-liver axis in mice. Sci Total Environ. 2024;935:173458.","journal-title":"Sci Total Environ"},{"issue":"4","key":"3832_CR203","doi-asserted-by":"publisher","DOI":"10.3390\/gels11040227","volume":"11","author":"S Ghasemi","year":"2025","unstructured":"Ghasemi S, Najafi M, Doroudian M, et al. Temperature- and pH-responsive poly(NIPAM-co-HEMA-co-AAm) nanogel as a smart vehicle for doxorubicin delivery; combating colorectal cancer. Gels. 2025;11(4):227.","journal-title":"Gels"},{"issue":"17","key":"3832_CR204","doi-asserted-by":"publisher","first-page":"20822","DOI":"10.1021\/acsami.3c03826","volume":"15","author":"RA Dop","year":"2023","unstructured":"Dop RA, Neill DR, Hasell T. Sulfur-polymer nanoparticles: preparation and antibacterial activity. ACS Appl Mater Interfaces. 2023;15(17):20822\u201332.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3832_CR205","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.125673","volume":"246","author":"S Yadav","year":"2023","unstructured":"Yadav S, Chamoli S, Kumar P, Maurya PK. Structural and functional insights in polysaccharides coated cerium oxide nanoparticles and their potential biomedical applications: a review. Int J Biol Macromol. 2023;246:125673.","journal-title":"Int J Biol Macromol"},{"key":"3832_CR206","doi-asserted-by":"publisher","first-page":"143004","DOI":"10.1016\/j.chemosphere.2024.143004","volume":"364","author":"C Shao","year":"2024","unstructured":"Shao C, Luo T, Wang S, et al. Selenium nanoparticles alleviates cadmium induced hepatotoxicity by inhibiting ferroptosis and oxidative stress in vivo and in vitro. Chemosphere. 2024;364:143004.","journal-title":"Chemosphere"},{"issue":"39","key":"3832_CR207","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202402999","volume":"34","author":"X Lin","year":"2024","unstructured":"Lin X, Li J, Wang J, Filppula AM, Zhang H, Zhao Y. Ion-specific hydrogel microcarriers with biomimetic niches for bioartifical liver system. Adv Funct Mater. 2024;34(39):2402999.","journal-title":"Adv Funct Mater"},{"key":"3832_CR208","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jconrel.2015.11.003","volume":"221","author":"T Lin Ts","year":"2016","unstructured":"Lin Ts T, Gao DY, Liu YC, et al. Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis. J Control Release. 2016;221:62\u201370.","journal-title":"J Control Release"},{"issue":"704","key":"3832_CR209","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq6225","volume":"15","author":"A Moreno-Lanceta","year":"2023","unstructured":"Moreno-Lanceta A, Medrano-Bosch M, Fundora Y, et al. RNF41 orchestrates macrophage-driven fibrosis resolution and hepatic regeneration. Sci Transl Med. 2023;15(704):eabq6225.","journal-title":"Sci Transl Med"},{"issue":"Pt B","key":"3832_CR210","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jcis.2024.08.239","volume":"678","author":"Y Yang","year":"2025","unstructured":"Yang Y, Chen Q, Liu Z, et al. Novel reduced heteropolyacid nanoparticles for effective treatment of drug-induced liver injury by manipulating reactive oxygen and nitrogen species and inflammatory signals. J Colloid Interface Sci. 2025;678(Pt B):174\u201387.","journal-title":"J Colloid Interface Sci"},{"key":"3832_CR211","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2024.108713","volume":"187","author":"A Rehman","year":"2024","unstructured":"Rehman A, Huang F, Zhang Z, et al. Nanoplastic contamination: impact on zebrafish liver metabolism and implications for aquatic environmental health. Environ Int. 2024;187:108713.","journal-title":"Environ Int"},{"issue":"1","key":"3832_CR212","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s11658-022-00384-y","volume":"27","author":"AT Gharavi","year":"2022","unstructured":"Gharavi AT, Hanjani NA, Movahed E, Doroudian M. The role of macrophage subtypes and exosomes in Immunomodulation. Cell Mol Biol Lett. 2022;27(1):83.","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"3832_CR213","doi-asserted-by":"publisher","first-page":"e2408906","DOI":"10.1002\/advs.202408906","volume":"12","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Hu K, Wang F, et al. Guanidine-Derived polymeric nanoinhibitors target the lysosomal V-ATPase and activate AMPK pathway to ameliorate liver lipid accumulation. Adv Sci (Weinh). 2025;12(1):e2408906.","journal-title":"Adv Sci (Weinh)"},{"key":"3832_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121499","volume":"615","author":"YJ Yee","year":"2022","unstructured":"Yee YJ, Benson HAE, Dass CR, Chen Y. Evaluation of novel conjugated Resveratrol polymeric nanoparticles in reduction of plasma degradation, hepatic metabolism and its augmentation of anticancer activity in vitro and in vivo. Int J Pharm. 2022;615:121499.","journal-title":"Int J Pharm"},{"issue":"11","key":"3832_CR215","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/s41589-024-01597-2","volume":"20","author":"M Li","year":"2024","unstructured":"Li M, Wang Z, Tao J, et al. Fructose-1,6-bisphosphatase 1 dephosphorylates and inhibits TERT for tumor suppression. Nat Chem Biol. 2024;20(11):1505\u201313.","journal-title":"Nat Chem Biol"},{"issue":"9","key":"3832_CR216","doi-asserted-by":"publisher","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","volume":"15","author":"B-M Chen","year":"2021","unstructured":"Chen B-M, Cheng T-L, Roffler SR. Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies. ACS Nano. 2021;15(9):14022\u201348.","journal-title":"ACS Nano"},{"issue":"6","key":"3832_CR217","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.1021\/acsnano.2c12193","volume":"17","author":"W-A Chen","year":"2023","unstructured":"Chen W-A, Chang D-Y, Chen B-M, Lin Y-C, Barenholz Y, Roffler SR. Antibodies against poly(ethylene glycol) activate innate immune cells and induce hypersensitivity reactions to pegylated nanomedicines. ACS Nano. 2023;17(6):5757\u201372.","journal-title":"ACS Nano"},{"issue":"9","key":"3832_CR218","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s44222-025-00321-6","volume":"3","author":"Y Chen","year":"2025","unstructured":"Chen Y, Su Y-C, Roffler SR. Polyethylene glycol immunogenicity in nanomedicine. Nat Rev Bioeng. 2025;3(9):742\u201360.","journal-title":"Nat Rev Bioeng"},{"issue":"11","key":"3832_CR219","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41563-024-02116-3","volume":"24","author":"Y Xiao","year":"2025","unstructured":"Xiao Y, Lian X, Sun Y, et al. High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics. Nat Mater. 2025;24(11):1840\u201351. https:\/\/doi.org\/10.1038\/s41563-024-02116-3.","journal-title":"Nat Mater"},{"issue":"4","key":"3832_CR220","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41565-023-01563-4","volume":"19","author":"J Kim","year":"2024","unstructured":"Kim J, Eygeris Y, Ryals RC, Jozi\u0107 A, Sahay G. Strategies for non-viral vectors targeting organs beyond the liver. Nat Nanotechnol. 2024;19(4):428\u201347.","journal-title":"Nat Nanotechnol"},{"issue":"43","key":"3832_CR221","doi-asserted-by":"publisher","first-page":"29421","DOI":"10.1021\/acsnano.4c12122","volume":"18","author":"D Ge","year":"2024","unstructured":"Ge D, An R, Xue L, et al. Developing cell-membrane-associated liposomes for liver diseases. ACS Nano. 2024;18(43):29421\u201338.","journal-title":"ACS Nano"},{"issue":"7","key":"3832_CR222","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s44160-025-00778-8","volume":"4","author":"C Feng","year":"2025","unstructured":"Feng C. Scalable and precise synthesis of polymer nanoparticles. Nat Synth. 2025;4(7):781\u20132.","journal-title":"Nat Synth"},{"key":"3832_CR223","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2020.213463","volume":"421","author":"C Song","year":"2020","unstructured":"Song C, Shen M, Rodrigues J, Mignani S, Majoral J-P, Shi X. Superstructured poly(amidoamine) dendrimer-based nanoconstructs as platforms for cancer nanomedicine: a concise review. Coord Chem Rev. 2020;421:213463.","journal-title":"Coord Chem Rev"},{"key":"3832_CR224","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103980","volume":"185","author":"M Ajam-Hosseini","year":"2023","unstructured":"Ajam-Hosseini M, Akhoondi F, Doroudian M. Nano based-oncolytic viruses for cancer therapy. Crit Rev Oncol Hematol. 2023;185:103980.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"3832_CR225","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/hep.29617","volume":"67","author":"S Aoki","year":"2018","unstructured":"Aoki S, Cobbold M, Zhu AX, Duda DG. Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage? Hepatology. 2018;67(3):826\u20138.","journal-title":"Hepatology"},{"issue":"7","key":"3832_CR226","doi-asserted-by":"publisher","first-page":"e1906360","DOI":"10.1002\/smll.201906360","volume":"16","author":"F Yang","year":"2020","unstructured":"Yang F, Medik Y, Li L, et al. Nanoparticle drug delivery can reduce the hepatotoxicity of therapeutic cargo. Small. 2020;16(7):e1906360.","journal-title":"Small"},{"key":"3832_CR227","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121567","volume":"616","author":"X Gao","year":"2022","unstructured":"Gao X, Zhang J, He Z, et al. Targeting delivery of synergistic dual drugs with elastic PEG-modified multi-functional nanoparticles for hepatocellular carcinoma therapy. Int J Pharm. 2022;616:121567.","journal-title":"Int J Pharm"},{"key":"3832_CR228","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114416","volume":"188","author":"C Hald Albertsen","year":"2022","unstructured":"Hald Albertsen C, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 2022;188:114416.","journal-title":"Adv Drug Deliv Rev"},{"issue":"sup2","key":"3832_CR229","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/21691401.2018.1457037","volume":"46","author":"T Saleh","year":"2018","unstructured":"Saleh T, Ahmed E, Yu L, et al. Silver nanoparticles improve structural stability and biocompatibility of decellularized porcine liver. Artif Cells Nanomed Biotechnol. 2018;46(sup2):273\u201384.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"11","key":"3832_CR230","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1557\/s43578-023-01003-y","volume":"38","author":"R Heidari","year":"2023","unstructured":"Heidari R, Sepahi Z, Mohammadi-Samani S, et al. Mesoporous silica application as an antidote of methotrexate and evaluation of the long-term oral administration: in vitro and in vivo study. J Mater Res. 2023;38(11):2930\u201342.","journal-title":"J Mater Res"},{"issue":"2","key":"3832_CR231","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2217\/nnm-2018-0455","volume":"15","author":"M Li","year":"2020","unstructured":"Li M, Wang Y, Jiang S, et al. Biodistribution and biocompatibility of glycyrrhetinic acid and galactose-modified chitosan nanoparticles as a novel targeting vehicle for hepatocellular carcinoma. Nanomedicine. 2020;15(2):145\u201361.","journal-title":"Nanomedicine"},{"issue":"1","key":"3832_CR232","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-020-0578-8","volume":"18","author":"HC Jan\u00dfen","year":"2020","unstructured":"Jan\u00dfen HC, Angrisani N, Kalies S, et al. Biodistribution, biocompatibility and targeted accumulation of magnetic nanoporous silica nanoparticles as drug carrier in orthopedics. J Nanobiotechnol. 2020;18(1):14.","journal-title":"J Nanobiotechnol"},{"key":"3832_CR233","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.actbio.2016.11.007","volume":"49","author":"D Shao","year":"2017","unstructured":"Shao D, Lu MM, Zhao YW, et al. The shape effect of magnetic mesoporous silica nanoparticles on endocytosis, biocompatibility and biodistribution. Acta Biomater. 2017;49:531\u201340.","journal-title":"Acta Biomater"},{"issue":"5","key":"3832_CR234","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1080\/17435390.2021.1916635","volume":"15","author":"CR Buhr","year":"2021","unstructured":"Buhr CR, Eckrich J, Kluenker M, et al. Determination of the LD(50) with the chick embryo chorioallantoic membrane (CAM) assay as a promising alternative in nanotoxicological evaluation. Nanotoxicology. 2021;15(5):690\u2013705.","journal-title":"Nanotoxicology"},{"key":"3832_CR235","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jcis.2023.11.109","volume":"656","author":"JQ Le","year":"2024","unstructured":"Le JQ, Song XH, Tong LW, et al. Dual-drug controllable co-assembly nanosystem for targeted and synergistic treatment of hepatocellular carcinoma. J Colloid Interface Sci. 2024;656:177\u201388.","journal-title":"J Colloid Interface Sci"},{"issue":"2","key":"3832_CR236","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/toxsci\/kfi256","volume":"88","author":"L Braydich-Stolle","year":"2005","unstructured":"Braydich-Stolle L, Hussain S, Schlager JJ, Hofmann MC. In vitro cytotoxicity of nanoparticles in mammalian germline stem cells. Toxicol Sci. 2005;88(2):412\u20139.","journal-title":"Toxicol Sci"},{"issue":"5","key":"3832_CR237","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41565-025-01925-0","volume":"20","author":"MA Dobrovolskaia","year":"2025","unstructured":"Dobrovolskaia MA. Better the devil you know than the devil you don\u2019t - PEG challenges in nanomedicine. Nat Nanotechnol. 2025;20(5):580\u20133.","journal-title":"Nat Nanotechnol"},{"key":"3832_CR238","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2024.102512","volume":"59","author":"K Chen","year":"2024","unstructured":"Chen K, Zheng C, Lv Y, et al. Complement opsonized protein corona activated by precoated immunoglobulin enables neutrophil-hitchhiking for rapid and enhanced drug delivery for acute liver failure recovery. Nano Today. 2024;59:102512.","journal-title":"Nano Today"},{"issue":"40","key":"3832_CR239","doi-asserted-by":"publisher","first-page":"35675","DOI":"10.1021\/acsnano.5c11552","volume":"19","author":"Y Qi","year":"2025","unstructured":"Qi Y, Fu Y, Wu X, et al. Flower-shaped lipid nanoparticles evade Apolipoprotein E-mediated liver tropism for safe and enhanced cytokine-based cancer immunotherapy. ACS Nano. 2025;19(40):35675\u201391.","journal-title":"ACS Nano"},{"key":"3832_CR240","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104731","volume":"86","author":"D Ezhilarasan","year":"2023","unstructured":"Ezhilarasan D, Shree Harini K. Nanodrug delivery: strategies to circumvent nanoparticle trafficking by Kupffer cells in the liver. J Drug Deliv Sci Technol. 2023;86:104731.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"8","key":"3832_CR241","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3390\/ph18081157","volume":"18","author":"SK Niazi","year":"2025","unstructured":"Niazi SK. Continuous manufacturing of recombinant drugs: comprehensive analysis of cost reduction strategies, regulatory pathways, and global implementation. Pharmaceuticals (Basel). 2025;18(8):1157. https:\/\/doi.org\/10.3390\/ph18081157.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"3832_CR242","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jhep.2011.01.006","volume":"55","author":"H Jaeschke","year":"2011","unstructured":"Jaeschke H, Ramachandran A. Reactive oxygen species in the normal and acutely injured liver. J Hepatol. 2011;55(1):227\u20138.","journal-title":"J Hepatol"},{"key":"3832_CR243","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103107","volume":"71","author":"YS Jung","year":"2024","unstructured":"Jung YS, Radhakrishnan K, Hammad S. ERR\u03b3-inducible FGF23 promotes alcoholic liver injury through enhancing CYP2E1 mediated hepatic oxidative stress. Redox Biol. 2024;71:103107.","journal-title":"Redox Biol"},{"issue":"1","key":"3832_CR244","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02375-x","volume":"24","author":"X Liang","year":"2025","unstructured":"Liang X, Weng J, You Z, et al. Oxidative stress in cancer: from tumor and microenvironment remodeling to therapeutic frontiers. Mol Cancer. 2025;24(1):219.","journal-title":"Mol Cancer"},{"issue":"1","key":"3832_CR245","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.molcel.2023.11.001","volume":"84","author":"F Hecht","year":"2024","unstructured":"Hecht F, Zocchi M, Alimohammadi F, Harris IS. Regulation of antioxidants in cancer. Mol Cell. 2024;84(1):23\u201333.","journal-title":"Mol Cell"},{"issue":"4","key":"3832_CR246","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41580-020-0225-0","volume":"21","author":"P Strzyz","year":"2020","unstructured":"Strzyz P. AMPK against NASH. Nat Rev Mol Cell Biol. 2020;21(4):181\u2013181.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"3832_CR247","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202210819","volume":"36","author":"YG Kim","year":"2024","unstructured":"Kim YG, Lee Y, Lee N, Soh M, Kim D, Hyeon T. Ceria-based therapeutic antioxidants for biomedical applications. Adv Mater. 2024;36(10):e2210819.","journal-title":"Adv Mater"},{"issue":"20","key":"3832_CR248","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202210412","volume":"35","author":"F Xiao","year":"2023","unstructured":"Xiao F, Chen Y, Qi J, Yao Q, Xie J, Jiang X. Multi-targeted peptide-modified gold nanoclusters for treating solid tumors in the liver. Adv Mater. 2023;35(20):2210412.","journal-title":"Adv Mater"},{"issue":"10","key":"3832_CR249","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17101292","volume":"17","author":"A Pusta","year":"2025","unstructured":"Pusta A, Tertis M, Ciocan B, et al. Aptamer-modified magnetic nanoparticles as targeted drug delivery systems for hepatocellular carcinoma. Pharmaceutics. 2025;17(10):1292.","journal-title":"Pharmaceutics"},{"issue":"15","key":"3832_CR250","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153804","volume":"15","author":"S Zanganeh","year":"2023","unstructured":"Zanganeh S, Abbasgholinejad E, Doroudian M, Esmaelizad N, Farjadian F, Benhabbour SR. The current landscape of glioblastoma biomarkers in body fluids. Cancers (Basel). 2023;15(15):3804.","journal-title":"Cancers (Basel)"},{"issue":"21","key":"3832_CR251","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202302217","volume":"13","author":"J Wang","year":"2024","unstructured":"Wang J, Wu X, Zhao J, Ren H, Zhao Y. Developing liver microphysiological systems for biomedical applications. Adv Healthc Mater. 2024;13(21):e2302217.","journal-title":"Adv Healthc Mater"},{"issue":"8","key":"3832_CR252","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1007\/s10570-022-04563-0","volume":"29","author":"W Kargupta","year":"2022","unstructured":"Kargupta W, Seifert R, Martinez M, Olson J, Tanner J, Batchelor W. Preparation and benchmarking of novel cellulose nanopaper. Cellulose. 2022;29(8):4393\u2013411.","journal-title":"Cellulose"},{"key":"3832_CR253","doi-asserted-by":"crossref","unstructured":"Abbasgholinejad E, Doroudian M, Soezi M, Farjadian F. Chapter 13 - Theranostics: silver nanoparticles mediated drug delivery. In: Kesharwani P, Jain NK, editors. Theranostics nanomaterials in drug delivery. Academic; 2025. pp. 231\u201352.","DOI":"10.1016\/B978-0-443-22044-9.00008-5"},{"key":"3832_CR254","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ultsonch.2014.10.006","volume":"23","author":"S Abbas","year":"2015","unstructured":"Abbas S, Karangwa E, Bashari M, et al. Fabrication of polymeric nanocapsules from curcumin-loaded nanoemulsion templates by self-assembly. Ultrason Sonochem. 2015;23:81\u201392.","journal-title":"Ultrason Sonochem"},{"key":"3832_CR255","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2020.126328","volume":"317","author":"C Qiu","year":"2020","unstructured":"Qiu C, Julian McClements D, Jin Z, et al. Resveratrol-loaded core-shell nanostructured delivery systems: cyclodextrin-based metal-organic nanocapsules prepared by ionic gelation. Food Chem. 2020;317:126328.","journal-title":"Food Chem"},{"issue":"3","key":"3832_CR256","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202400412","volume":"8","author":"S Gholamian","year":"2025","unstructured":"Gholamian S, Baghaee P, Doroudian M. Nanotechnology in gene editing: pioneering CRISPR-Cas delivery systems to tackle antibiotic resistance. Adv Ther. 2025;8(3):2400412.","journal-title":"Adv Ther"},{"key":"3832_CR257","unstructured":"Wang J, Huang D, Chen D, Ren H, Zhao Y. Emerging Functional Porous Scaffolds for Liver Tissue Engineering. Advanced Healthcare Materials. n\/a(n\/a):2403741."},{"key":"3832_CR258","doi-asserted-by":"crossref","unstructured":"Yu M, Mathew A, Liu D, et al. Microfluidics for formulation and Scale-Up production of nanoparticles for biopharma industry. In: Lamprou DA, Weaver E, editors. Microfluidics in pharmaceutical sciences: Formulation, drug Delivery, Screening, and diagnostics. Springer Nature Switzerland; 2024. pp. 395\u2013420.","DOI":"10.1007\/978-3-031-60717-2_16"},{"issue":"9","key":"3832_CR259","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.3390\/cancers14092238","volume":"14","author":"M Cascallar","year":"2022","unstructured":"Cascallar M, Alijas S, Pensado-L\u00f3pez A, et al. What zebrafish and nanotechnology can offer for cancer treatments in the age of personalized medicine. Cancers (Basel). 2022;14(9):2238. https:\/\/doi.org\/10.3390\/cancers14092238.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3832_CR260","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1021\/acs.nanolett.8b03434","volume":"19","author":"J Lazarovits","year":"2019","unstructured":"Lazarovits J, Chen YY, Song F, et al. Synthesis of patient-specific nanomaterials. Nano Lett. 2019;19(1):116\u201323.","journal-title":"Nano Lett"},{"key":"3832_CR261","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114360","volume":"187","author":"M Wu","year":"2022","unstructured":"Wu M, Niu X, Zhang R, Ping Xu Z. Two-dimensional nanomaterials for tumor microenvironment modulation and anticancer therapy. Adv Drug Deliv Rev. 2022;187:114360.","journal-title":"Adv Drug Deliv Rev"},{"key":"3832_CR262","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ijpharm.2019.03.041","volume":"562","author":"M Dul","year":"2019","unstructured":"Dul M, Nikolic T, Stefanidou M, et al. Conjugation of a peptide autoantigen to gold nanoparticles for intradermally administered antigen specific immunotherapy. Int J Pharm. 2019;562:303\u201312.","journal-title":"Int J Pharm"},{"issue":"6","key":"3832_CR263","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.jtho.2017.03.005","volume":"12","author":"AB Schrock","year":"2017","unstructured":"Schrock AB, Li SD, Frampton GM, et al. Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling. J Thorac Oncol. 2017;12(6):932\u201342.","journal-title":"J Thorac Oncol"},{"key":"3832_CR264","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2024.102300","volume":"56","author":"AG Pershina","year":"2024","unstructured":"Pershina AG, Efimova LV, Brikunova OY, et al. Nano-bio interaction of magnetic nanoparticles with cells in a tumor at the single-cell level. Nano Today. 2024;56:102300.","journal-title":"Nano Today"},{"issue":"6640","key":"3832_CR265","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1126\/science.ade3925","volume":"380","author":"J Zecha","year":"2023","unstructured":"Zecha J, Bayer FP, Wiechmann S, et al. Decrypting drug actions and protein modifications by dose- and time-resolved proteomics. Science. 2023;380(6640):93\u2013101.","journal-title":"Science"},{"issue":"1","key":"3832_CR266","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01399-3","volume":"8","author":"S Qiu","year":"2023","unstructured":"Qiu S, Cai Y, Yao H, et al. Small molecule metabolites: discovery of biomarkers and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):132.","journal-title":"Signal Transduct Target Ther"},{"key":"3832_CR267","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2022.128820","volume":"434","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Zhang Y, Li Y, et al. Integrative proteomics and metabolomics approach to elucidate metabolic dysfunction induced by silica nanoparticles in hepatocytes. J Hazard Mater. 2022;434:128820.","journal-title":"J Hazard Mater"},{"key":"3832_CR268","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202510239","author":"H Bae","year":"2025","unstructured":"Bae H, Ji H, Konstantinov K, et al. Artificial intelligence-driven nanoarchitectonics for smart targeted drug delivery. Adv Mater. 2025. https:\/\/doi.org\/10.1002\/adma.202510239.","journal-title":"Adv Mater"},{"key":"3832_CR269","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114194","volume":"184","author":"N Serov","year":"2022","unstructured":"Serov N, Vinogradov V. Artificial intelligence to bring nanomedicine to life. Adv Drug Deliv Rev. 2022;184:114194.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"3832_CR270","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1021\/acs.macromol.2c02249","volume":"56","author":"B Ma","year":"2023","unstructured":"Ma B, Finan NJ, Jany D, Deagen ME, Schadler LS, Brinson LC. Machine-learning-assisted understanding of polymer nanocomposites composition\u2013property relationship: a case study of nanomine database. Macromolecules. 2023;56(11):3945\u201353.","journal-title":"Macromolecules"},{"issue":"1","key":"3832_CR271","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02050-7","volume":"21","author":"J Wan","year":"2023","unstructured":"Wan J, He Z, Peng R, et al. Injectable photocrosslinking spherical hydrogel-encapsulated targeting peptide-modified engineered exosomes for osteoarthritis therapy. J Nanobiotechnol. 2023;21(1):284.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"3832_CR272","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02845-2","volume":"22","author":"Y Ma","year":"2024","unstructured":"Ma Y, Dong J, Li M, Du X, Yan Z, Tian W. An antimicrobial microneedle patch promotes functional healing of infected wounds through controlled release of adipose tissue-derived apoptotic vesicles. J Nanobiotechnology. 2024;22(1):579.","journal-title":"J Nanobiotechnology"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03832-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03832-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03832-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:02:05Z","timestamp":1766574125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-025-03832-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":272,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3832"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03832-x","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors gave their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"786"}}